Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates

@article{Ferreira2007EffectsOS,
  title={Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates},
  author={Ema Ferreira and Ana Maria Carceller and Claire Agogu{\'e} and Brigitte Martin and Martin St-Andr{\'e} and Diane Francoeur and Anick B{\'e}rard},
  journal={Pediatrics},
  year={2007},
  volume={119},
  pages={52 - 59}
}
OBJECTIVES. Our goals were to (a) describe neonatal behavioral signs in a group of newborns exposed in utero to selective serotonin reuptake inhibitors or venlafaxine at the time of delivery, (b) compare the rate of neonatal behavioral signs, prematurity, and admission to specialized neonatal care between a group of exposed and unexposed newborns, and (c) compare the effects in exposed preterm and term newborns. PATIENTS AND METHODS. This was a retrospective cohort study including mothers… 
View on AAP
ncbi.nlm.nih.gov
128 Citations
Highly Influential Citations
4
Background Citations
19
Methods Citations
2
Results Citations
3

Tables from this paper

128 Citations

Citation Type

Citation Type

Serotonin Reuptake Inhibitor-Induced Perinatal Complications
  • S. Gentile
  • Medicine, Psychology
    Paediatric drugs
  • 2007
TLDR
The opportunity of tapering and discontinuing SRIs in late pregnancy should be taken into consideration, although to date the evidence to support such a clinical decision is preliminary.
Effects of in-utero exposure to selective serotonin reuptake inhibitors and venlafaxine on term and preterm infants.
TLDR
In-utero SSRI exposure was associated with increased neonatal care at birth, differences in Apgar scores compared with controls, and increased NICU admissions and higher sertraline doses were associated with poorer outcomes.
Serotonin and poor neonatal adaptation after antidepressant exposure in utero
TLDR
A transient disturbance of the neonatal serotonergic system may play a role in the aetiology of PNA, and other factors, including the presence of maternal psychological distress, also seem to playing a role.
Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval Prolongation in Newborns
TLDR
Antepartum use of selective serotonin-reuptake inhibitor antidepressants is associated with QTc interval prolongation in exposed neonates and additional research using a standardized protocol is needed to determine whether exposure to selective antidepressants in late pregnancy is also associated with arrhythmias.
Prolongation in Newborns Antenatal Use of Selective Serotonin-Reuptake Inhibitors and QT Interval
TLDR
Antepartum use of selective serotonin-reuptake inhibitor antidepressants is associated with QTc interval prolongation in exposed neonates, and additional research using a standardized protocol is needed to determine whether exposure to selective antidepressants in late pregnancy is also associated with arrhythmias.
Neonatal Outcomes After Late-Gestation Exposure to Selective Serotonin Reuptake Inhibitors
TLDR
The results add to the growing body of evidence of an association between SSRI exposure during pregnancy and a range of adverse neonatal outcomes, but the potential for confounding according to severity of underlying maternal psychiatric illness requires further investigation.
Prenatal exposure to serotonin reuptake inhibitors: a case report
TLDR
Two premature twins were born to a woman who had used paroxetine during pregnancy for an anxiety-depression disorder, where they showed prolonged RDS, cardiovascular malformations, and facial dysmorphisms, which partially disappeared during the following weeks, although alterations of tone persisted even at discharge.
Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.
Pharmacology Review: Maternal Selective Serotonin Reuptake Inhibitor Use and Neurologic Effects on the Neonate
TLDR
The link between markers of fetal central nervous damage and maternal SSRI use is discussed, the literature reporting various short- and long-term neurologic effects in neonates after maternal use of SSRIs is evaluated, and recommendations for the management of and parental counseling about various adverse neurologic outcomes of SSri use during pregnancy are developed.
The use of psychotropic medication during pregnancy: how about the newborn?
TLDR
Infants are at risk of developing symptoms of Poor Neonatal Adaptation after exposure to psychotropic drugs in utero, breastfeeding is presumably protective for development of PNA, and Phenobarbital is a safe therapeutic option.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
[Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy].
TLDR
This study confirms the relative benignity of SSRI exposure during late pregnancy and suggests the risk of hemorrhagic symptoms or hyponatremia deserves to be recalled to medical teams who take in charge newborns exposed to SSRI.
Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
TLDR
Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.
TLDR
Data support an association between the maternal use of SSRIs in late pregnancy and PPHN in the offspring; these findings should be taken into account in decisions as to whether to continue the use ofSSRIs during pregnancy.
Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.
TLDR
Neonatal abstinence syndrome occurs in 30% of neonates exposed to SSRIs in utero and these neonates should be monitored for at least 48 hours after birth, particularly in neonates who develop severe symptoms.
Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
TLDR
Recommendations to taper the dosage of antidepressants in pregnant women during the last trimester are only partially evidence-based and may put the depressed mother-to-be and her baby at an unreasonable health risk.
Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.
TLDR
Results provide the first systematic evidence that women who use SSRIs during pregnancy have healthy, full-birth-weight newborn infants who show disruptions in a wide range of neurobehavioral outcomes.
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
TLDR
Five cases of neonatal withdrawal syndrome after third trimester in utero SSRI exposure are reported, with Symptoms were irritability, constant crying, shivering, increased tonus, eating and sleeping difficulties and convulsions.
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
TLDR
While transient neonatal symptoms were found in infants after single-agent prenatal exposure to SSRIs, the addition of clonazepam appeared to alter paroxetine metabolism, leading to increased drug levels and risk for transient Neonatal symptoms.
Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis
Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.
...
1
2
3
4
5
...